Welcome Dr. Chloe Wormser to Hope Veterinary Specialists

Last month we introduced you to our new neurologist, Dr. David Brewer but our Hope team continues to grow! We are pleased  to introduce you to Dr. Chloe Wormser, who joins our team of surgeons this month. 

Dr.  Chloe  Wormser is originally from Chicago and graduated from the University of Pennsylvania School of Veterinary Medicine in 2011.  She continued her training at Penn, completing a rotating internship followed by a residency in small animal surgery.  Dr.  Wormser is a Diplomate of the American College of Veterinary Surgeons. 

Dr.  Wormser's surgical interests include microvascular surgery, urinary tract surgery, and minimally invasive surgery.  She has authored several journal articles in peer-reviewed journals, with research focused on feline renal transplantation and ureteral disease.

The majority of her free time is spent exploring the Pennsylvania dog parks with her French Bulldog, Pumpernickel.

Minimally Invasive Surgery Now at Hope VS! 
Hope Veterinary Specialists is pleased to announce that we are now offering minimally invasive surgical procedures.  Many of you have likely already heard of minimally invasive surgery, which involves the use of small incisions into the thorax (thoracoscopy), abdomen (laparoscopy), or joints (arthroscopy).  

With 4 board certified surgeons trained in minimally invasive surgery and a board certified anesthesiologist to oversee anesthesia for these cases, HOPE is excited to start performing these procedures for referring veterinary community and clients! 

For more information on minimally invasive surgery at HOPE, please call us at 610-296-2099 or clink on the link below.

VetDC Achieves Key Regulatory Milestone, Nears FDA Approval of TANOVEA for Canine Lymphoma
"This is a significant milestone for VetDC, as we are one step closer to introducing the first FDA-approved drug for use in dogs with lymphoma"

VetDC, Inc., a veterinary cancer therapeutics company, today announced that the Company has received three major technical section complete letters for  TanoveaTM (rabacfosadine)  from the U.S. Food and Drug Administration's Center for Veterinary Medicine (FDA-CVM). Upon approval, Tanovea will be the first on-label therapeutic option for use in dogs with lymphoma, one of the most common cancers afflicting companion animals today.

Hereditary Disorders in Dogs More Common Than Initially Thought, According to New Study
Puppy genetics take a leap with a new medical breakthrough. A recent study revealed that a lot of hereditary disorders of canine are more widespread than originally believed.

According to a report from the  University of Helsinki, the team tested nearly 7,000 dogs of about 230 different breeds for predisposition to almost 100 genetic disorders. They discovered that one out of six dogs had at least one of the tested disease predisposing genetic variants in their genome.

Trial to extend life of dogs shows 'significant improvements' in heart health, say scientists 

A 24-dog trial at the University of Washington to test the safety of rapamycin showed the drug improved cardiac function without significant side effects. The results are part of an ongoing study of the drug in pets to determine whether it can prolong the life of dogs and possibly humans and mitigate some of the problems associated with aging.

OCTOBER 26, 2016 

Simon Dennis, BVetMed, MVM, DECVIM (Cardiology)

Heart disease is highly prevalent in cats, with multiple studies confirming that the most common group of acquired feline cardiac disease, the cardiomyopathies, affect 15% of healthy cats.   With the AVMA reporting that there were over 74 million cats owned in the US in 2012, that represents at least 11 million cats with cardiac disease in the US alone.  While a notable proportion of cats with cardiac disease have a normal life expectancy and quality of life, cats with severe or advanced disease have a high morbidity and mortality from heart failure, sudden death or arterial thromboembolism.  Identifying those cats at high risk for adverse consequences of their disease and treating them appropriately remain two of the biggest challenges in feline cardiology.  Unfortunately there is little consensus among practitioners and cardiologists regarding the 'best' way.  This reflects the difficulties faced with diagnosing and classifying cardiac disease in cats, the high prevalence of functional murmurs in cats, and the paucity of evidence to support the benefit of therapy for both preclinical cardiomyopathies and cats with heart failure. 

This talk will provide practical advice for veterinarians in general practice, using the tools in their practice, to identify cats with, or at risk of, cardiac disease and to recognize cats at the highest risk for heart failure and ATE.  The talk will also discuss which cases may benefit from therapy, what therapies have evidence to support their use, when to start them, and what therapies have questionable benefit or may be harmful.